Phase I/II Study of KP-100IT in Acute Spinal Cord Injury

Summary

This study is randomized, double-blind, placebo-controlled Phase I/II study designed to evaluate safety and efficacy of KP-100IT, code of Hepatocyte Growth Factor (HGF) formulation for intrathecal injection, as a treatment for acute spinal cord injury. The study is conducted at two clinical sites in Japan.

Timeline

Start

2014-06-30

Primary completion

2017-12-21

Completion

2018-07-31

Drugs

Indications